Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem Cell Transplantation With Campath-1H for Advanced Mycosis Fungoides/Sezary Syndrome
NCT00047060Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2002
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Complete Response Rate at 36 months. Started Jul 2002; status: completed.
02
Drugs
alemtuzumab
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT00047060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00047060.